/
Other
Skin Disease
20
Pipeline Programs↗
3
Active Trials↗
11
Companies Involved↗
Skin Disease is an emerging landscape with 20 programs across 11 companies. The most active players are Sanofi.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical20
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
85%
Small molecule
17 of 20 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.
Analysis
Trial Status
13
clinical trials
Completed6 · 46%
Unknown status2 · 15%
Not yet recruiting2 · 15%
Withdrawn1 · 8%
Recruiting1 · 8%
Terminated1 · 8%
Clinical Trials
Trial Activity
13 trials
Evolution of Chronic Inflammatory Skin Diseases
Not yet recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT07708896·5,000 enrolled
Anakinra for Inflammatory Pustular Skin Diseases
Completed·National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 2·NCT01794117·18 enrolled
Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease
Withdrawn·—·Phase 1·NCT04656704
The Safety and Effectiveness of Local Injection of Antihistamines in Treatment of Inflammatory Skin Diseases
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT04937101·78 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)